Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc.OBIO · Entity 434 | Director | July 20, 2023 | July 25, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Orchestra BioMed Holdings, Inc.
Report date July 20, 2023 · Filed July 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per share ("Common Stock")SEC Table I · non-derivative | Direct | 20,913 |
Reported balance
After 2023-07-20 transaction · row 1
1 source rowRow 1 · 2023-07-20 · Grant · Acquired 16,667 · Balance 20,913 F1: Represents restricted stock units that vest in full on July 20, 2024, subject to the Reporting Person's continued service with Orchestra BioMed Holdings, Inc. on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest in full on July 20, 2024, subject to the Reporting Person's continued service with Orchestra BioMed Holdings, Inc. on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2023 Filed Jul 25, 2023 01:00 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-083556 · tm2321855-11_4seq1.xml · nonDerivative · entry 1 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,913 F1 · shares: Represents restricted stock units that vest in full on July 20, 2024, subject to the Reporting Person's continued service with Orchestra BioMed Holdings, Inc. on such vesting date. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionRight to Receive Earnout Shares · Derivative | 55,783 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · derivative · entry 8 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures Synecor, LP Disclosed balance after: 55,783 Underlying: Common Stock · 55,783 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F3 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionRight to Receive Earnout Shares · Derivative | 228,073 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · derivative · entry 7 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures II, LP Disclosed balance after: 228,073 Underlying: Common Stock · 228,073 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F3 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionRight to Receive Earnout Shares · Derivative | 43,761 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · derivative · entry 6 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures II NY, LP Disclosed balance after: 43,761 Underlying: Common Stock · 43,761 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F3 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionRight to Receive Earnout Shares · Derivative | 758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · derivative · entry 5 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 758 Underlying: Common Stock · 758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock") | 55,783 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · nonDerivative · entry 4 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures Synecor, LP Disclosed balance after: 312,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F3 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock") | 228,073 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · nonDerivative · entry 3 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures II, LP Disclosed balance after: 1,277,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F3 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock") | 43,761 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · nonDerivative · entry 2 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures II NY, LP Disclosed balance after: 245,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F3 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock") | 758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · nonDerivative · entry 1 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantStock Options (Right to Buy) · Derivative | 23,250 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0000899243-23-002966 · doc4.xml · derivative · entry 11 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,250 Underlying: Common Stock · 23,250 shares Expires 2032-08-25 F14 · price: Received in connection with the Business Combination in exchange for options to acquire 50,000 shares of Orchestra common stock for $4.65 per share. F13 · derivative.exercise_date: The stock option vests in quarterly installments with a one year cliff beginning on August 18, 2023. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantStock Options (Right to Buy) · Derivative | 6,975 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0000899243-23-002966 · doc4.xml · derivative · entry 10 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975 Underlying: Common Stock · 6,975 shares Expires 2029-08-06 F12 · price: Received in connection with the Business Combination in exchange for options to acquire 15,000 shares of Orchestra common stock for $2.00 per share. F10 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantStock Options (Right to Buy) · Derivative | 18,600 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0000899243-23-002966 · doc4.xml · derivative · entry 9 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2028-08-07 F11 · price: Received in connection with the Business Combination in exchange for options to acquire 40,000 shares of Orchestra common stock for $2.00 per share. F10 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantWarrants (Right to Buy) · Derivative | 519 | Not disclosed Strike: $21.51 | Not disclosed |
DisclosureSEC source: 0000899243-23-002966 · doc4.xml · derivative · entry 8 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ascent Biomedical Ventures Synecor, LP Disclosed balance after: 519 Underlying: Common Stock · 519 shares Expires 2023-05-31 F9 · price: Received in connection with the Business Combination in exchange for warrants to acquire 1,117 shares of Orchestra common stock for $10.00 per share. F6 · derivative.exercise_date: The warrants are immediately exercisable in full. F4 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantWarrants (Right to Buy) · Derivative | 136,097 | Not disclosed Strike: $21.51 | Not disclosed |
DisclosureSEC source: 0000899243-23-002966 · doc4.xml · derivative · entry 7 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ascent Biomedical Ventures II, LP Disclosed balance after: 136,097 Underlying: Common Stock · 136,097 shares Expires 2023-05-31 F8 · price: Received in connection with the Business Combination in exchange for warrants to acquire 292,682 shares of Orchestra common stock for $10.00 per share. F6 · derivative.exercise_date: The warrants are immediately exercisable in full. F4 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantWarrants (Right to Buy) · Derivative | 43,940 | Not disclosed Strike: $21.51 | Not disclosed |
DisclosureSEC source: 0000899243-23-002966 · doc4.xml · derivative · entry 6 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ascent Biomedical Ventures II NY, LP Disclosed balance after: 43,940 Underlying: Common Stock · 43,940 shares Expires 2023-05-31 F7 · price: Received in connection with the Business Combination in exchange for warrants to acquire 94,494 shares of Orchestra common stock for $10.00 per share. F6 · derivative.exercise_date: The warrants are immediately exercisable in full. F4 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock | 256,623 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-002966 · doc4.xml · nonDerivative · entry 4 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ascent Biomedical Ventures Synecor, LP Disclosed balance after: 256,623 F3 · price: Received in exchange for shares of Orchestra common stock that automatically converted into shares of New Orchestra common stock on a 1 for 0.465 basis upon the closing date of the Business Combination. F4 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock | 1,049,224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-002966 · doc4.xml · nonDerivative · entry 3 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ascent Biomedical Ventures II, LP Disclosed balance after: 1,049,224 F3 · price: Received in exchange for shares of Orchestra common stock that automatically converted into shares of New Orchestra common stock on a 1 for 0.465 basis upon the closing date of the Business Combination. F4 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock | 201,319 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-002966 · doc4.xml · nonDerivative · entry 2 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ascent Biomedical Ventures II NY, LP Disclosed balance after: 201,319 F3 · price: Received in exchange for shares of Orchestra common stock that automatically converted into shares of New Orchestra common stock on a 1 for 0.465 basis upon the closing date of the Business Combination. F4 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock | 3,488 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-002966 · doc4.xml · nonDerivative · entry 1 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,488 F1 · shares: Represents restricted stock awards ("RSAs") that vest in two equal annual installments beginning on April 12, 2023, subject to the reporting person's continued service with Orchestra BioMed Holdings, Inc. ("New Orchestra") on such vesting date. F2 · price: Received in connection with the business combination of Orchestra BioMed, Inc. ("Orchestra") with Health Sciences Acquisitions Corporation 2 (the "Business Combination") in exchange for 1,621 RSAs of Orchestra. Read SEC document |
| January 26, 2023 Filed May 8, 2023 11:47 UTC Amendment | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantRight to Receive Earnout Shares · Derivative | 111,566 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056864 · tm2314913-2_4aseq1.xml · derivative · entry 4 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures Synecor, LP Disclosed balance after: 111,566 Underlying: Common Stock · 111,566 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| January 26, 2023 Filed May 8, 2023 11:47 UTC Amendment | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantRight to Receive Earnout Shares · Derivative | 456,146 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056864 · tm2314913-2_4aseq1.xml · derivative · entry 3 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures II, LP Disclosed balance after: 456,146 Underlying: Common Stock · 456,146 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. Read SEC document |
| January 26, 2023 Filed May 8, 2023 11:47 UTC Amendment | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantRight to Receive Earnout Shares · Derivative | 87,522 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056864 · tm2314913-2_4aseq1.xml · derivative · entry 2 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures II NY, LP Disclosed balance after: 87,522 Underlying: Common Stock · 87,522 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. Read SEC document |
| January 26, 2023 Filed May 8, 2023 11:47 UTC Amendment | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantRight to Receive Earnout Shares · Derivative | 1,516 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056864 · tm2314913-2_4aseq1.xml · derivative · entry 1 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,516 Underlying: Common Stock · 1,516 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.